Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090095Aexternal-prioritypatent/EP1862468A1/de
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Publication of CR10477ApublicationCriticalpatent/CR10477A/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Steroid Compounds
(AREA)
Medicinal Preparation
(AREA)
Heat Sensitive Colour Forming Recording
(AREA)
Abstract
En particular, dos formas cristalinas de ansolvato/anhidrato de este compuesto, las formas polimorficas I y II. Solvatos cristalinos, por ejemplo, los solvatos de metanol y etanol de 11B-(4-acetilfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-1-nor-17c-pregna-4,9-dien-3-ona, como precursores para la preparacion de ambas formas polimorficas I y II.
CR10477A2006-06-022008-12-02FORMAS CRISTALINAS DE 11B-(ACETILFENIL)-20,20,21,21,21,-PENTAFLUORO-17-HIDROXI-19-NOR-17a-PREGNA-4,9-DIEN-3-ONA
CR10477A
(es)
Formas cristalinas de 11beta - (4 - acetilfenil) - 20, 20, 21, 21, 21 - pentafluoro - 17 - hidroxi - 19 - nor - 17alfa - pregna - 4, 9 - dien - 3 - ona, metodos para su obtencion y preparaciones farmaceuticas que las contienen para emplear en el tratamiento de miomas y cancer de mamas.